Clinical trial
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients…
NCT00052299 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00052299 |
|---|---|
| Title | Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia |
| Official title | Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP |
| Acronym | AML-17 |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Collaborators | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, etoposide, gemtuzumab ozogamicin, idarubicin, mitoxantrone hydrochloride |
| Enrollment | 472 |
| Start date | Sep 1, 2002 |
| Primary completion | Jan 1, 2008 |
| Completion | Feb 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 27, 2012 |
| Countries | Austria, Belgium, France, Germany, Italy, Netherlands, Portugal |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: